➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Moodys
Mallinckrodt
AstraZeneca
Colorcon

Last Updated: July 4, 2020

DrugPatentWatch Database Preview

ZEGERID OTC Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Zegerid Otc, and when can generic versions of Zegerid Otc launch?

Zegerid Otc is a drug marketed by Bayer Healthcare Llc and is included in two NDAs.

The generic ingredient in ZEGERID OTC is omeprazole; sodium bicarbonate. There are one hundred and thirty-one drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the omeprazole; sodium bicarbonate profile page.

Drug patent expirations by year for ZEGERID OTC
Recent Clinical Trials for ZEGERID OTC

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
NorginePhase 3
BayerPhase 1
NorginePhase 1

See all ZEGERID OTC clinical trials

Paragraph IV (Patent) Challenges for ZEGERID OTC
Tradename Dosage Ingredient NDA Submissiondate
ZEGERID OTC CAPSULE;ORAL omeprazole; sodium bicarbonate 022281 2010-04-20

US Patents and Regulatory Information for ZEGERID OTC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Healthcare Llc ZEGERID OTC omeprazole; sodium bicarbonate CAPSULE;ORAL 022281-001 Dec 1, 2009 OTC Yes Yes   Start Trial   Start Trial   Start Trial
Bayer Healthcare Llc ZEGERID OTC omeprazole; sodium bicarbonate FOR SUSPENSION;ORAL 022283-001 Jun 17, 2013 OTC Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ZEGERID OTC

Supplementary Protection Certificates for ZEGERID OTC

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0984957 SPC/GB11/013 United Kingdom   Start Trial PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
1411900 SPC/GB11/015 United Kingdom   Start Trial PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Moodys
Mallinckrodt
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.